2-deoxy-2[(18)F]fluoro-D-glucose positron emission tomography–computed tomography in rheumatological diseases

2-deoxy-2[(18)F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a number of inflammatory cells. Exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Subesinghe, Manil, Bhuva, Shaheel, Arumalla, Nikita, Cope, Andrew, D’Cruz, David, Subesinghe, Sujith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071551/
https://www.ncbi.nlm.nih.gov/pubmed/34463703
http://dx.doi.org/10.1093/rheumatology/keab675
Descripción
Sumario:2-deoxy-2[(18)F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a number of inflammatory cells. Exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wide range of infective and inflammatory diseases. Rheumatological diseases can affect multiple sites within the musculoskeletal system alongside multi-organ extra-articular disease manifestations. Inflammation is central to these diseases, making FDG PET-CT a logical choice. In this review article we describe the various applications of FDG PET-CT in rheumatological diseases using illustrative examples to highlight the beneficial role of FDG PET-CT in each case.

Ejemplares similares